ReviewJournal of clinical medicine2020
Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies.Reviews in cardiovascular medicine · 2026Review
- Perioperative Patient Blood Management: Evidence-Based Strategies for Surgeons and Anesthesiologists: A Narrative Review.Journal of clinical medicine · 2026Review
- Hematuria Management in Patients on Antiplatelet Medications After Acute Coronary Syndrome: A Review of the Current Evidence and Recommendations.Reviews in cardiovascular medicine · 2026Review
- "Massive" haemoptysis.Breathe (Sheffield, England) · 2025Article
- Acquired platelet disorders.Frontiers in medicine · 2025Review
- Predicting bleeding risk in PAD patients on antiplatelets using TEG coagulation testing.Journal of surgery and research · 2025Article
- SDIMMMER: A Proposed Clinical Approach to Optimize Cellular Physiology in Regenerative Medicine.Life (Basel, Switzerland) · 2024Article
- ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events.European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Review
- Effect of perioperative aspirin continuation on bleeding after pneumonectomy.Thoracic cancer · 2023Article
- Reversal of Platelet Inhibition in Patients Receiving Ticagrelor.Reviews in cardiovascular medicine · 2022Review
- Platelet storage pool disorder in pregnancy: Utilising thromboelastography to guide a risk-based delivery plan.Obstetric medicine · 2022Article
- Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.Frontiers in cardiovascular medicine · 2022Review
- Viscoelastic Testing and Coagulopathy of Traumatic Brain Injury.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleeding complications are common in patients treated with antiplatelet agents (APA), but their management relies on poor evidence. Therefore, practical guidelines and guidance documents are mainly based on expert opinion. The French Working Group on Perioperative Haemostasis provided proposals in 2018 to enhance clinical decisions regarding the management of APA-treated patients with a bleeding event. In light of these proposals, this review discusses the evidence and uncertainties of the management of patients with a bleeding event while on antiplatelet therapy. Platelet transfusion is the main option as an attempt to neutralise the effect of APA on primary haemostasis. Nevertheless, efficacy of platelet transfusion to mitigate clinical consequences of bleeding in patients treated with APA depends on the type of antiplatelet therapy, the time from the last intake, the mechanism (spontaneous versus traumatic) and site of bleeding and the criteria of efficacy (in vitro, in vivo). Specific antidotes for APA neutralisation are needed, especially for ticagrelor, but are not available yet. Despite the amount of information that platelet function tests are expected to give, little data support the clinical benefit of using such tests for the management of bleeding events in patients treated or potentially treated with APA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.